| 5GTY: reference: Discovery and characterization of a novel irreversible EGFR mutants selective and potent kinase inhibitor CHMFL-EGFR-26 with a distinct binding mode., Hu C, Wang A, Wu H, Qi Z, Li X, Yan XE, Chen C, Yu K, Zou F, Wang W, Wang W, Wu J, Liu J, Wang B, Wang L, Ren T, Zhang S, Yun CH, Liu J, Liu Q, Oncotarget. 2017 Mar 14;8(11):18359-18372. doi: 10.18632/oncotarget.15443. PMID: 28407693 |
This OCA 
Structure page
uses Jmol,
developed by the Jmol Development Team
(documentation).